Fatty Liver as a Metabolic Disease: A Physician's Guide

The Metabolic Identity of Fatty Liver Disease

For many years, fatty liver disease was treated primarily as a liver problem. Physicians ordered liver function tests, performed ultrasounds, and counselled patients on weight loss, often without examining the broader metabolic context that drove the condition in the first place. That approach is now considered incomplete.

The global medical community formally redefined this condition in 2023, replacing the older term Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The name change reflects a profound shift in clinical understanding. Fatty liver is not simply about fat accumulating in liver cells. It is a manifestation of systemic metabolic dysfunction, closely entangled with insulin resistance, visceral adiposity, dyslipidaemia, type 2 diabetes, and cardiovascular disease. In India, the Indian National Association for Study of the Liver (INASL) continues to use the older NAFLD terminology in parallel while broader adoption of MASLD progresses, but the underlying clinical approach is converging rapidly toward a metabolic framework.

This shift has significant implications for how physicians screen, diagnose, and manage patients. Recognising fatty liver as a metabolic disease transforms it from a hepatologist's responsibility alone into a condition that general physicians, diabetologists, endocrinologists, and cardiologists must all actively identify and address. For Indian doctors, this recognition is especially urgent given the scale and severity of the problem within the country's patient population.

Why India Faces a Uniquely Severe Challenge

India's metabolic burden is substantial and growing. Research published in 2025 from the MAP Study, which analysed data from 13,750 adults across 105 diabetes and endocrine clinics across six geographic zones in India, found the prevalence of MASLD to be 68.2 percent among individuals attending these clinics, with fibrosis present in 33.7 percent of cases. The highest burden was observed in North India, particularly in Uttarakhand, where rates reached 80 percent.

A separate meta-analysis reported a pooled prevalence of 38.6 percent in Indian adults generally. Among patients with type 2 diabetes specifically, the prevalence of fatty liver disease rises to between 55 and 70 percent, while metabolic steatohepatitis (the more inflammatory form of the disease) affects 30 to 40 percent of diabetic patients.

What makes this particularly challenging in India is what researchers have described as the lean NAFLD phenotype. A significant proportion of Indian patients develop fatty liver at body mass index (BMI) values that would be considered normal or borderline by Western standards. This happens because Indians tend to accumulate greater amounts of visceral fat at lower body weights and exhibit higher levels of insulin resistance compared to Caucasian populations at equivalent BMI measurements. The practical consequence is that a physician who screens only obese or overweight patients will miss a substantial subset of Indian patients who have clinically significant liver disease despite appearing metabolically normal by conventional measures.

A 2026 analysis by InBody India noted that Indians develop insulin resistance five to ten years earlier than Caucasian populations, and show rates of fatty liver disease three to four times higher at normal BMI levels. This phenotype is now well-documented in major international medical journals, including The Lancet and Diabetologia.

The Core Metabolic Conditions Physicians Should Screen For

Because fatty liver is a systemic metabolic condition, the physician's screening approach needs to go well beyond ordering a liver ultrasound. The following are the key metabolic domains that every physician evaluating a patient with known or suspected fatty liver disease should assess.

Insulin Resistance and Type 2 Diabetes

Insulin resistance is the central pathophysiologic driver of MASLD. The liver becomes a reservoir for excess fat primarily because peripheral insulin resistance leads to increased lipolysis in adipose tissue, flooding the portal circulation with free fatty acids. The liver then attempts to compensate by converting these excess lipids into triglycerides and storing them within hepatocytes.

Every patient with fatty liver disease should be evaluated for insulin resistance. In clinical practice, fasting plasma glucose, HbA1c, and a two-hour oral glucose tolerance test are the most accessible tools. The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) index, calculated from fasting glucose and fasting insulin levels, provides a more direct estimate. Indian guidelines now recommend that physicians use HOMA-IR as part of a structured metabolic assessment for patients presenting with fatty liver, particularly those who do not meet conventional thresholds for diabetes or prediabetes.

The bidirectional relationship between fatty liver and diabetes is important. Nearly half of all patients with MASLD are diabetic, but the reverse is also true: half of patients with type 2 diabetes have clinically significant fatty liver disease. Recognising this overlap should prompt physicians in both endocrinology clinics and general medicine practice to screen systematically.

Dyslipidaemia

Abnormal lipid profiles, particularly elevated serum triglycerides and low HDL cholesterol, are closely associated with fatty liver disease. These abnormalities reflect the underlying state of insulin resistance and hepatic lipid overload. The liver in a state of metabolic dysfunction exports excessive VLDL particles into the circulation, driving up triglyceride levels while simultaneously suppressing HDL production.

Physicians should order a complete fasting lipid profile for all patients with fatty liver. Hypertriglyceridaemia above 150 mg/dL and HDL cholesterol below 40 mg/dL in men or 50 mg/dL in women are recognised components of metabolic syndrome and, in the context of fatty liver, indicate a higher risk of liver fibrosis progression. Elevated LDL cholesterol, while less directly linked to liver fat accumulation, contributes significantly to the cardiovascular risk profile that these patients carry.

Hypertension

Systemic hypertension is a recognised cardiometabolic comorbidity in patients with MASLD. The mechanisms connecting fatty liver disease with elevated blood pressure include increased sympathetic nervous system activity driven by insulin resistance, activation of the renin-angiotensin-aldosterone system, and endothelial dysfunction mediated by oxidative stress. Blood pressure measurement and monitoring should be a routine part of every clinical encounter involving a patient with known fatty liver disease.

Obesity and Central Adiposity

BMI remains a useful but imperfect screening tool, especially in Indian patients. Waist circumference is a more reliable indicator of visceral fat and metabolic risk in this population. Indian clinical guidelines recommend using ethnicity-specific cut-offs: a waist circumference above 90 cm in men and above 80 cm in women identifies abdominal obesity in Indian adults, even when BMI falls below 25.

Body composition analysis, particularly measurement of visceral adipose tissue through tools such as bioelectric impedance or imaging, provides an even more detailed picture. However, at the level of routine clinical practice, waist circumference combined with BMI and a careful physical examination provides sufficient information to stratify metabolic risk.

Cardiovascular Risk Assessment

Patients with MASLD carry a significantly elevated risk of cardiovascular disease. Cardiovascular events, not liver failure, are the leading cause of mortality in patients with fatty liver disease. This is an important point for both physicians and patients to understand. The metabolic milieu that drives fat accumulation in the liver, consisting of insulin resistance, dyslipidaemia, hypertension, and systemic inflammation, simultaneously promotes atherosclerosis and cardiac dysfunction.

Physicians managing patients with fatty liver disease should therefore incorporate cardiovascular risk tools into their assessment. The Framingham Risk Score, SCORE2 guidelines, or India-specific cardiovascular risk calculators provide useful estimates. Physicians should assess for subclinical atherosclerosis, left ventricular hypertrophy, and diastolic dysfunction in patients with multiple metabolic comorbidities.

Screening Tools and Non-Invasive Diagnostics

The diagnosis of fatty liver disease has become increasingly accessible through non-invasive tools. Liver biopsy remains the gold standard for staging fibrosis, but is neither practical nor necessary for initial screening in most patients.

Abdominal ultrasound is the most commonly used first-line imaging tool in Indian clinical practice. It is widely available, affordable, and can detect moderate to severe hepatic steatosis reliably. However, it has limited sensitivity for mild steatosis and cannot assess fibrosis accurately.

Transient elastography, commonly performed using FibroScan, has become the preferred non-invasive tool for assessing both liver stiffness (fibrosis) and controlled attenuation parameter (a proxy for steatosis). The MAP Study, published in 2025, used FibroScan as its primary assessment tool across 105 clinics in India, demonstrating the growing feasibility of this approach in routine clinical settings. FibroScan is now available in most major urban tertiary care centres and many secondary care hospitals across India.

Non-invasive blood-based scores such as the FIB-4 index (calculated from age, AST, ALT, and platelet count) and the NAFLD Fibrosis Score help physicians identify patients who require further evaluation with elastography or specialist referral. A FIB-4 score below 1.30 effectively rules out significant fibrosis in most patients, while a score above 2.67 warrants hepatology referral.

The Role of the Physician in a Multidisciplinary Model

The expert consensus statement published by Indian diabetologists in 2025 in Diabetes, Obesity and Metabolism emphasised that the asymptomatic nature of MASLD has historically led to underdiagnosis and undertreatment, particularly in primary care and endocrinology settings. The majority of high-risk patients present to general practitioners, physicians, and endocrinologists rather than to hepatologists.

This creates both a responsibility and an opportunity. Physicians at the front lines of patient care are uniquely positioned to identify fatty liver disease early, before significant fibrosis develops, and to initiate metabolic management that benefits not only the liver but the entire cardiometabolic profile.

A structured approach involves four steps. First, identify patients at metabolic risk using clinical criteria, including obesity, type 2 diabetes, dyslipidaemia, and hypertension. Second, screen these patients with appropriate imaging and blood tests. Third, assess the degree of liver involvement using non-invasive scores and elastography where available. Fourth, refer patients with significant fibrosis or diagnostic uncertainty to hepatology while continuing to manage metabolic risk factors collaboratively.

HealthVoice, as a doctor-focused professional community platform, provides physicians across India with access to expert clinical discussions, emerging guidelines, and association-led updates that support exactly this kind of collaborative, informed medical practice. For physicians looking to stay current on evolving MASLD guidelines, connect with specialist colleagues, or participate in clinical awareness initiatives, HealthVoice serves as a credible and accessible professional resource.

Management Principles: Beyond the Liver

Because MASLD is a metabolic disease, its management is fundamentally metabolic. There is no approved pharmacotherapy specifically for liver fat reduction in India as of 2025, though clinical trials of several agents are ongoing. Management therefore, centres on lifestyle modification and the treatment of coexisting metabolic conditions.

Sustained weight loss of seven to ten percent of body weight through dietary modification and physical activity has been shown to reduce hepatic steatosis significantly and, in some cases, reverse early fibrosis. A Mediterranean-style dietary pattern, rich in whole grains, vegetables, legumes, and unsaturated fats, has demonstrated particular benefit for hepatic fat reduction and is increasingly recommended in Indian clinical guidelines, with appropriate adaptation to local food patterns.

Pharmacological management of diabetes, dyslipidaemia, and hypertension should be optimised. GLP-1 receptor agonists and SGLT-2 inhibitors, both now available in India, have shown hepatic benefits beyond glycaemic control and are increasingly considered in patients with fatty liver and type 2 diabetes. Statins are safe and beneficial in patients with fatty liver disease and dyslipidaemia, contrary to older concerns about hepatotoxicity, and should not be withheld.

Conclusion: Reframing the Clinical Conversation

Fatty liver disease is not a condition that sits neatly within the boundaries of any single medical specialty. It is the liver's visible expression of a body under metabolic stress. For physicians in India, where metabolic risk manifests at lower thresholds of obesity and at younger ages than in Western populations, recognising this reality and acting on it early is both a clinical and a public health imperative.

The screening framework that serves patients best is one that is comprehensive, metabolic in orientation, and multidisciplinary in execution. When physicians approach a patient with fatty liver disease by asking what metabolic conditions are driving this and what systemic risks must be addressed alongside the liver, they move from reactive management to genuine preventive care. That shift, scaled across India's vast and growing patient population, can meaningfully reduce the burden of liver disease, cardiovascular disease, and metabolic illness for millions of people.

Frequently Asked Questions

Can a person with normal body weight have fatty liver disease?

Yes, and this is especially relevant for Indian patients. A significant proportion of Indians develop metabolic dysfunction-associated steatotic liver disease at body mass index values that fall within the normal range. This occurs because Indians tend to accumulate more visceral fat at lower body weights and develop insulin resistance earlier than Western populations. Physicians should not exclude fatty liver disease on the basis of normal BMI alone, particularly in patients with other metabolic risk factors such as dyslipidaemia or prediabetes.

What blood tests should a physician order when screening for fatty liver-related metabolic conditions?

A comprehensive metabolic screening for a patient with known or suspected fatty liver disease should include fasting plasma glucose, HbA1c, fasting insulin with HOMA-IR calculation, a complete lipid profile, liver function tests including AST and ALT with platelet count for FIB-4 calculation, thyroid function tests, and, where available, a fasting serum uric acid level. An abdominal ultrasound should accompany this blood work in the initial evaluation.

Is fatty liver disease reversible?

In its early stages, fatty liver disease is reversible. Significant and sustained weight loss, typically seven to ten percent of body weight, along with optimised management of coexisting conditions such as diabetes, hypertension, and dyslipidaemia, has been shown to reduce or eliminate hepatic steatosis. Once significant fibrosis develops, reversal becomes more difficult, which is why early screening and intervention are critically important. Patients with advanced fibrosis require specialist hepatological care alongside continued metabolic management.

#FattyLiverDisease #MetabolicHealth